Clinical utility of the risperidone formulations in the management of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 611-620

  Madaan, Vishal ^a   Bestha, Durga P ^b   Kolli, Venkata ^b   Jauhari, Saurabh ^b   Burket, Roger C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Formulation; Risperidone; Schizophrenia; Side effects

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADD ON THERAPY; ADOLESCENCE; AGITATION; AKATHISIA; BODY WEIGHT; COGNITION; DIABETES MELLITUS; DISPERSIBLE TABLET; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FIRST EPISODE PSYCHOSIS; GALACTORRHEA; GYNECOMASTIA; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE PAIN; INSOMNIA; LENGTH OF STAY; MAINTENANCE THERAPY; METABOLIC DISORDER; METABOLISM; MULTIPLE CYCLE TREATMENT; MUSCLE HYPERTONIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; POWDER; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT; WEIGHT GAIN;

EID: 80955122614     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s14385     Document Type: Review

References (66)

1. Colpaert FC. Discovering risperidone: the LSD model of psychopathology. Nat Rev Drug Discov. 2003;2(4):315-320.
2. Van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25(6):1687-1699.
3. Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry. 2006;39(6):209-212.
4. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81-86.
5. Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994;114(1):9-23.
6. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. October 7, 2009;(4):CD007474.
7. Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry. 2003;60(5):458-464.
8. Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62(9):961-970.
9. Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. January 20, 2010;(1): CD006918.
10. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry. 2009;14(4):429-447.
11. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000440.
12. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000440.
13. Crespo-Facorro B, Pérez-Iglesias RO, Mata I, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, openlabel 1-year follow-up comparison. J Psychopharmacol. 2011. doi: 10.1177/0269881110388332.
14. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626.
15. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
16. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
17. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009; 23(8):649-659.
18. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007;15(5):245-258.
19. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52: S13-S19.
20. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-1132.
21. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1): 111-117.
22. Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585-594.
23. Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat. 2010;7:19-26.
24. Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509.
25. Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149-154.
26. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531-539.
27. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus D, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharm. 2008;28(2):210-213.
28. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S29-S36.
29. Beitchman JH, Childhood schizophrenia: a review and comparison of adult onset schizophrenia. Psychiatric Clin North Am. 1985;8(4): 793-814.
30. Madaan V. Risperidone: a review of efficacy studies in adolescents with schizophrenia. Drugs Today (Barc). 2009;45(1):55-62.
31. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double blind, placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611-621.
32. Pandina G, Kushner S, Singer J, et al. Comparison of two risperidone dose ranges inadolescents with schizophrenia [abstract]. 54th Annu Meet Am Acad Child Adolesc Psychiatry. October 23-28, 2007; Boston, MA.
33. Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15(6):885-892.
34. Toren P, Loar N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998;59(12):644-656.
35. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia:an open pilot study. J Am Acad Child Adolesc Psychiatry. 1997;36(5):694-700.
36. Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995;34(10):1292-1296.
37. Correll CU, Penzer JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am. 2006;15(1):177-206.
38. Lloyd A, Horan W, Borgaro SR, Stokes JM, Pogge DL, Harvey PD. Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol. 1998;8(2):133-141.
39. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3):CD006324.
40. Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458-468.
41. Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther. 2008;30(9):1565-1589.
42. Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):208-211.
43. Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116(2-3):101-106.
44. Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol. 2002;17(2):95-98.
45. Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24(3)233-238.
46. Stip E. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci. 2000;25(2):137-153.
47. Medscape. Drugs, Diseases and Procedures: Risperidone. Available at: http://reference.medscape.com/drug/risperdal-consta-risperidone-342986#0.
48. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-425.
49. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47(6): 716-719.
50. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531-540.
51. Wooten J. Metabolic effects of atypical antipsychotics. South Med J. 2007;100(8):771-772.
52. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. J Clin Psychiatry. 2004; 65(2):267-272.
53. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041-1050.
54. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- vs second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406-411.
55. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics - a review. Hum Psychopharmacol. 2010;25(4): 281-297.
56. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009;31 Pt 1:1345-1359.
57. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6): 477-492.
58. Taylor D, Paton C, Kapur S. The Maudsley Prescribing guidelines. 10th ed. London, UK: Informa Healthcare; 2009.
59. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59(4):337-345.
60. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163(10):1821-1825.
61. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.
62. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33(9):2061-2079.
63. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376.
64. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6): 553-564.
65. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
66. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6): 571-578.